BTNL9
- Known as:
- BTNL9
- Catalog number:
- 002733A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- BTNL9
Related genes to: BTNL9
- Gene:
- BTNL9 NIH gene
- Name:
- butyrophilin like 9
- Previous symbol:
- -
- Synonyms:
- FLJ32535, BTN8
- Chromosome:
- 5q35.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-05
- Date modifiied:
- 2016-01-06
Related products to: BTNL9
Related articles to: BTNL9
- Butyrophilin-like 9 (BTNL9), a member of the immunoglobulin superfamily containing a bZIP-like domain, has a poorly defined role in cancer. Here, we identify BTNL9 as a non-canonical transcriptional regulator and investigate its function in non-small cell lung cancer (NSCLC). Coiled-coil prediction, native PAGE, and co-immunoprecipitation demonstrated BTNL9 homodimerization via its bZIP-like region, while subcellular fractionation and immunofluorescence confirmed its presence in both the nucleus and cytoplasm. Chromatin immunoprecipitation sequencing (ChIP-seq) analysis identified 9709 BTNL9-associated genomic regions, including sites proximal to transcription start sites, with enrichment of a cytosine-rich motif. Whether chromatin association reflects direct DNA binding or indirect co-regulatory interaction remains to be experimentally confirmed. Integrated transcriptomic and protein analyses revealed that BTNL9 overexpression represses genes involved in cell cycle progression and DNA replication while activating a subset of p53-associated pathways. Consistently, functional assays showed that increased BTNL9 expression induces cell cycle arrest, suppresses proliferation and clonogenicity, and inhibits tumor growth in xenograft models. In addition, cytotoxicity assays demonstrated enhanced sensitivity to bortezomib, with context-dependent effects on etoposide response. Analysis of public clinical datasets further showed that low BTNL9 expression is associated with advanced tumor stage, reduced remission rates, and poorer survival outcomes in NSCLC. These findings identify BTNL9 as a non-canonical tumor-suppressive transcriptional regulator with potential biomarker relevance in NSCLC. - Source: PubMed
Publication date: 2026/07/24
Ng Wooi LoonYadollahi PedramCho Hwa JinKang Mi SeonChoi Inhak - Endothelial cells (ECs) are key structural and functional components of the blood-brain barrier (BBB). Mouse models are frequently used to study EC biology within the BBB, yet the extent to which human and mouse BBB ECs share conserved transcriptomic features remains unclear. Here, we systematically compare transcriptomic profiles of BBB capillary ECs from adult mice and humans. - Source: PubMed
Publication date: 2026/03/12
Miao YuyangWang JianhaoLi WeihanMäe Maarja AndaloussiJeansson MarieMuhl LarsHe Liqun - Pancreatic cancer (PC) is an aggressive malignancy. As a member of the BTN/BTNL family, BTNL9 has been identified as a tumor suppressor in breast cancer, lung adenocarcinoma, and colon cancer; however, its role and underlying mechanisms in PC remain to be elucidated. - Source: PubMed
Xiao MaoLuo Zhi-YanYu Ai-RuXu KeZhou Wei - Understanding regulatory mechanisms like epigenetics can help improve beef production, carcass, and meat quality. Epigenetic states are dynamic and shaped by the environment, but due to limited studies and costly detection methods, alternative approaches are needed. - Source: PubMed
Publication date: 2025/06/27
Afonso JulianaJun Shim WooFigueiredo Cardoso TainãBruscadin Jennifer JéssicaOliveira de Lima AndressaJarles da Silva Diniz WellisonSilva-Vignato BárbaraSoares Garcia IngridLiang Andre Tan WeiSilva Neubern de Oliveira PriscilaSilva Mello Cesar AlineBarreto Mourão GersonZerlotini AdhemarLehmann Coutinho LuizRufino Salinas Fortes MarinaCorreia de Almeida Regitano Luciana - Lung adenocarcinoma (LUAD) is a major cause of cancer mortality. Considering the critical role of tumor infiltrating lymphocytes in effective immunotherapy, this study was designed to screen molecular markers related to tumor infiltrating cells in LUAD, aiming to improve immunotherapy response during LUAD therapy. - Source: PubMed
Publication date: 2025/05/08
Chen ZhenZhang Yongjun